What's New

2017.3.10

Bayer and Kyoto University Extend Collaborative Efforts to Identify Candidates for Research Projects

Bayer and Kyoto University Society-Academia Collaboration for Innovation (KU-SACI) in Japan had signed a two-year scouting agreement to jointly identify candidates for possible research projects to advance drug discovery and conducted collaborative investigations since 2015. In these two years, we deepened understandings of each other’s science through several AGORA meetings and invited presentations.  We are now in discussion with multiple scientists of Kyoto University for collaborative research opportunities.  Hence, we agreed to extend the agreement for another two years and continue to look for research projects for drug discovery in collaboration. Under the extended agreement, both parties continues to focus on identifying and proceeding projects, in which Kyoto University’s basic research expertise is applied to advance drug discovery in the key research areas of Bayer.

Director General. Shinji Asonuma (Kyoto University) and President. Heike Prinz (Bayer Yakuhin)